Literature DB >> 16879613

The HS:19 serostrain of Campylobacter jejuni has a hyaluronic acid-type capsular polysaccharide with a nonstoichiometric sorbose branch and O-methyl phosphoramidate group.

David J McNally1, Harold C Jarrell, Nam H Khieu, Jianjun Li, Evgeny Vinogradov, Dennis M Whitfield, Christine M Szymanski, Jean-Robert Brisson.   

Abstract

A recent study that examined multiple strains of Campylobacter jejuni reported that HS:19, a serostrain that has been associated with the onset of Guillain-Barré syndrome, had unidentified labile, capsular polysaccharide (CPS) structures. In this study, we expand on this observation by using current glyco-analytical technologies to characterize these unknown groups. Capillary electrophoresis electrospray ionization MS and NMR analysis with a cryogenically cooled probe (cold probe) of CPS purified using a gentle enzymatic method revealed a hyaluronic acid-type [-4)-beta-D-GlcA6NGro-(1-3)-beta-D-GlcNAc-(1-]n repeating unit, where NGro is 2-aminoglycerol. A labile alpha-sorbofuranose branch located at C2 of GlcA was determined to have the L configuration using a novel pyranose oxidase assay and is the first report of this sugar in a bacterial glycan. A labile O-methyl phosphoramidate group, CH3OP(O)(NH2)(OR) (MeOPN), was found at C4 of GlcNAc. Structural heterogeneity of the CPS was due to nonstoichiometric glycosylation with sorbose at C2 of GlcA and the nonstoichiometric, variably methylated phosphoramidate group. Examination of whole bacterial cells using high-resolution magic angle spinning NMR revealed that the MeOPN group is a prominent feature on the cell surface for this serostrain. These results are reminiscent of those in the 11168 and HS:1 strains and suggest that decoration of CPS with nonstoichiometric elements such as keto sugars and the phosphoramidate is a common mechanism used by this bacterium to produce a structurally complex surface glycan from a limited number of genes. The findings of this work with the HS:19 serostrain now present a means to explore the role of CPS as a virulence factor in C. jejuni.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879613     DOI: 10.1111/j.1742-4658.2006.05401.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  10 in total

1.  Campylobacter capsule and lipooligosaccharide confer resistance to serum and cationic antimicrobials.

Authors:  Thormika Keo; Jennifer Collins; Pratima Kunwar; Martin J Blaser; Nicole M Iovine
Journal:  Virulence       Date:  2011-01-01       Impact factor: 5.882

2.  Discrimination of major capsular types of Campylobacter jejuni by multiplex PCR.

Authors:  Frédéric Poly; Oralak Serichatalergs; Marc Schulman; Jennifer Ju; Cory N Cates; Margaret Kanipes; Carl Mason; Patricia Guerry
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

3.  The Campylobacter jejuni NCTC11168 capsule prevents excessive cytokine production by dendritic cells.

Authors:  Anna Rose; Emily Kay; Brendan W Wren; Margaret J Dallman
Journal:  Med Microbiol Immunol       Date:  2011-08-24       Impact factor: 3.402

4.  Functional and Structural Characterization of the UDP-Glucose Dehydrogenase Involved in Capsular Polysaccharide Biosynthesis from Campylobacter jejuni.

Authors:  Alexander S Riegert; Frank M Raushel
Journal:  Biochemistry       Date:  2021-02-23       Impact factor: 3.162

5.  Functional Characterization of Two PLP-Dependent Enzymes Involved in Capsular Polysaccharide Biosynthesis from Campylobacter jejuni.

Authors:  Alexander S Riegert; Tamari Narindoshvili; Adriana Coricello; Nigel G J Richards; Frank M Raushel
Journal:  Biochemistry       Date:  2021-09-10       Impact factor: 3.321

6.  Primary isolation strain determines both phage type and receptors recognised by Campylobacter jejuni bacteriophages.

Authors:  Martine C Holst Sørensen; Yilmaz Emre Gencay; Tina Birk; Signe Berg Baldvinsson; Claudia Jäckel; Jens A Hammerl; Christina S Vegge; Horst Neve; Lone Brøndsted
Journal:  PLoS One       Date:  2015-01-13       Impact factor: 3.240

7.  Host-specific differences in the response of cultured macrophages to Campylobacter jejuni capsule and O-methyl phosphoramidate mutants.

Authors:  Sungwon Kim; Andrea Vela; Sara M Clohisey; Spiridoula Athanasiadou; Pete Kaiser; Mark P Stevens; Lonneke Vervelde
Journal:  Vet Res       Date:  2018-01-09       Impact factor: 3.683

Review 8.  Bacterial glycosylation, it's complicated.

Authors:  Christine M Szymanski
Journal:  Front Mol Biosci       Date:  2022-09-30

9.  Biological roles of the O-methyl phosphoramidate capsule modification in Campylobacter jejuni.

Authors:  Lieke B van Alphen; Cory Q Wenzel; Michele R Richards; Christopher Fodor; Roger A Ashmus; Martin Stahl; Andrey V Karlyshev; Brendan W Wren; Alain Stintzi; William G Miller; Todd L Lowary; Christine M Szymanski
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

10.  Biomolecule sulphation and novel methylations related to Guillain-Barré syndrome-associated Campylobacter jejuni serotype HS:19.

Authors:  Astrid P Heikema; Nikolaos Strepis; Deborah Horst-Kreft; Steven Huynh; Aldert Zomer; David J Kelly; Kerry K Cooper; Craig T Parker
Journal:  Microb Genom       Date:  2021-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.